Home › Compare › AULRF vs ABBV
AULRF yields 0.06% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, AULRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AULRF + ABBV for your $10,000?
AURELIUS Equity Opportunities SE & Co. KGaA is a private equity firm specializing in acquisitions, growth, complex transaction structures/carve outs, add on acquisitions, redemption of existing creditors, management buyouts, management buy-ins, P2Ps, industry consolidation, strategic acquisitions in special target industries for existing platform investments in lower middle market companies. The firm acquires, restructures and eventually sells companies in special situations including corporate spin-offs, corporate carve-outs, platform build-up succession issues, and privately held companies with issues. It seeks to invest in company spin-offs and medium-sized companies with unresolved succession, significant operational problems, and balance sheet problems due to high debt levels. The firm considers investments in private and public companies, which are primarily operating in industrial enterprises, Industrials & chemicals, information technology, business services, lifestyle, consumer goods, food and beverage, and telecoms, media, and technology (TMT). It seeks to invest in companies headquartered in Europe with the focus on European Developed Markets & Nordic region. The firm typically invests up to €250 million ($278.97 million) and between €5 ($5.6 million) and €80 million ($89.27 million) per deal in companies with sales between €30 million ($33.5 million) and €750 million ($838.54 million) and EBITDA margin from negative to more than 15 percent. In the UK, the firm invests up to £70 million ($93.5 million) in businesses with revenues between £30 million ($34.99 million) and £1000 million ($1331.14 million). It seeks to acquire majority stake, preferably 100 percent stake in underperforming businesses with development potential. The firm prefers to invest in equity. It seeks to exit its investments through sale to private, institutional or industrial investors or through an IPO. AURELIUS Equity Opportunities SE & Co. KGaA was founded on March 20, 2006, and is based in Grünwald, Germany with additional offices in Amsterdam, Netherlands; London, United Kingdom; Madrid, Spain; Milan, Italy; Munich; Germany; Stockholm, Sweden and Dusseldorf, North Rhine-Westphalia.
Full AULRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.